Nexalis Therapeutics Limited (ASX:NX1)

Nexalis Therapeutics Revenue

Nexalis Therapeutics had revenue of 630.10K AUD in the half year ending June 30, 2026, with 419.05% growth. This brings the company's revenue in the last twelve months to 1.07M, up 28.04% year-over-year. In the year 2025, Nexalis Therapeutics had annual revenue of 986.43K with 145.50% growth.

• Revenue (ttm): 1.07M
• Revenue Growth: +28.04%
• P/S Ratio: 2.38
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 2.53M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	986.43K	584.62K	145.50%
Dec 31, 2024	401.81K	-802.24K	-66.63%
Dec 31, 2023	1.20M	1.18M	4,755.02%
Dec 31, 2022	24.80K	-156.94K	-86.35%
Dec 31, 2021	181.74K	159.61K	721.35%

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 16, 2026

Data Sources Report a data error